Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'
Executive Summary
Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.
You may also be interested in...
EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body
The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.
Servier and generics firms to appeal EU verdict on perindopril 'sweetheart' deals
The European Commission has imposed fines totaling Euros 427.7 million on Servier and five producers of generic medicines for anti-competitive practices – a decision that the French drug maker says sets a "regrettable precedent" for industries that rely on intellectual property1,2.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.